Results 11 to 20 of about 21,842 (260)

Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation

open access: yesClinical Hematology International, 2022
Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT.
Sayako Yuda   +3 more
doaj   +2 more sources

How to manage the initiation of apomorphine therapy without antiemetic pretreatment: A review of the literature

open access: yesClinical Parkinsonism & Related Disorders, 2023
Introduction: Pretreatment with the antiemetic trimethobenzamide has been recommended practice in the United States (US) to address the risk of nausea and vomiting during initiation of apomorphine treatment.
Stuart H. Isaacson   +3 more
doaj   +4 more sources

A retrospective review of treatment patterns of antiemetic agents for chemotherapy-induced nausea and vomiting

open access: yesSAGE Open Medicine, 2018
Objectives: To evaluate the treatment pattern of antiemetic agents used for chemotherapy-induced nausea and vomiting in a tertiary hospital in Saudi Arabia. Methods: Over a period of 7 weeks, all new chemotherapy order sheets were collected and evaluated
Abdulrahman Alamri   +3 more
doaj   +3 more sources

Diphenidol Has No Actual Broad Antiemetic Activity in Dogs and Ferrets

open access: yesJournal of Pharmacological Sciences, 2004
Previous studies showed that diphenidol was effective on emetogens-induced pica, eating of non-nutritive substances, in rats, a model analogous to emesis in other species.
Hiroe Nakayama   +6 more
doaj   +2 more sources

Analysis of Antiemetic Use After Initiation of Hormone Therapy [PDF]

open access: yes, 2022
This cross-sectional study investigates the occurrence of the prescribing cascade of antiemetic after hormone ...
Lund, Lars Christian; id_orcid   +6 more
core   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Evidence for Bell-Shaped Dose-Response Emetic Effects of Temsirolimus and Analogs: The Broad-Spectrum Antiemetic Efficacy of a Large Dose of Temsirolimus Against Diverse Emetogens in the Least Shrew (Cryptotis parva)

open access: yesFrontiers in Pharmacology, 2022
Temsirolimus is a prodrug form of sirolimus (rapamycin). With its analogs (everolimus, ridaforolimus, and rapamycin), it forms a group of anticancer agents that block the activity of one of the two mammalian targets of rapamycin (mTOR) complexes, mTORC1.
Louiza Belkacemi   +2 more
doaj   +1 more source

Comparative Study of Lidocaine and Palonosetron Pretreatment in Reduction of Propofol Induced Injection Pain [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2018
Introduction: Propofol is very popular as an induction agent in modern day anaesthesia because of its favourable pharmacodynamics and fewer side effects. Any pain pre or post-anaesthesia leads to patient dissatisfaction.
Suruchi Ambasta, Swagat Mahapatra
doaj   +1 more source

Cyclic vomiting syndrome (CVS) responsive to single-dose olanzapine: a case report [PDF]

open access: yesExploration of Neuroscience
Cyclic vomiting syndrome (CVS) is a rare disorder in which stereotypical periods of intermittent nausea and vomiting last between hours and over a week.
Sara Sipilä   +4 more
doaj   +1 more source

Monitoring the adherence to an adapted evidence-based clinical practice guideline on antiemetics in 669 patients with cancer receiving 1451 chemotherapy doses at a University oncology center in Saudi Arabia

open access: yesJournal of Nature and Science of Medicine, 2021
Objectives: Chemotherapy-induced nausea and vomiting (CINV) is a common medication safety issue among cancer patients worldwide. However, there remains a research gap on adherence to the clinical practice guidelines (CPGs) for antiemetic medications to ...
Haya Fahad Al-Salloum   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy